Yes, obviously there isn’t one cancer, but about every cancer is different. So yeah I give you that. Now, my other argument is you can make the same or more money with one time, possible curative therapies than with live prolonging one. See for example Kymriah. Sure, big and small pharma invest most in development were they can expect a high revenue. Either were there is a big patient population or a small population which have a high medical need. (And therefore are willing to pay a high price).
No opioids, hmm, well, KETAMIN!